CURRENT MEDICATIONS OVERVIEW,,
MEDICATION,GENE(S),PRESCRIBING CONSIDERATIONS BASED ON myDNA TEST
"Esomeprazole(Nexium)",CYP2C19,"Minor – result should be considered as may affect medicationresponse"
"Nortriptyline",CYP2D6,"Minor – result should be considered as may affect medicationresponse"
"Omeprazole",CYP2C19,"Minor – result should be considered as may affect medicationresponse"
"Fluoxetine","CYP2C9CYP2D6",Usual prescribing considerations apply
MEDICATIONS THAT DO NOT HAVE PRESCRIBING CONSIDERATIONS BASED ON myDNA TEST,,
"ramipril, amlodipine, naproxen, topiramate, zolmitriptan, ethinylestradiol / levonorgestrel (Levonorgestrel AndEthinyl Estradiol Tablets, 0.1 Mg/0.02 Mg)",,
MEDICATIONS WITH MAJOR PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
Antiplatelet drugs,Clopidogrel,CYP2C19,Reduced / inadequate response,CPIC2
MEDICATIONS WITH MINOR PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
"ADHD -miscellaneous agents",Atomoxetine,CYP2D6,Adverse effects,-
Antiarrhythmics,Flecainide,CYP2D6,Adverse effects,DPWG3
"",Propafenone,CYP2D6,Adverse effects,DPWG3
"Antidepressants -other",Mirtazapine,"CYP2D6CYP1A2",Altered response,-
"",Moclobemide,CYP2C19,Adverse effects,-
"Antidepressants -serotoninnoradrenalinereuptake inhibitors",Duloxetine,"CYP2D6CYP1A2",Reduced / inadequate response,-
"",Venlafaxine,CYP2D6,Adverse effects,DPWG3
"Antidepressants -SSRIs",Citalopram,CYP2C19,Adverse effects,CPIC4
"",Escitalopram,CYP2C19,Adverse effects,CPIC4
"",Paroxetine,CYP2D6,Adverse effects,CPIC4
"",Sertraline,CYP2C19,Adverse effects,CPIC4
"Antidepressants -tricyclicantidepressants",Amitriptyline,"CYP2D6CYP2C19",Altered response,CPIC1
"",Clomipramine,"CYP2D6CYP2C19",Altered response,CPIC1
"",Desipramine,CYP2D6,Adverse effects,CPIC1
"",Doxepin,"CYP2D6CYP2C19",Altered response,CPIC1
"",Imipramine,"CYP2D6CYP2C19",Altered response,CPIC1
"",Nortriptyline,CYP2D6,Adverse effects,CPIC1
Antidiabetics,Gliclazide,"CYP2C9CYP2C19","Increased therapeutic and/oradverse effects",-
Antiemetics,Ondansetron,CYP2D6,"Increased therapeutic and/oradverse effects",CPIC5
Antifungals - Azoles,Voriconazole,CYP2C19,"Increased therapeutic and/oradverse effects",CPIC6
Antihistamines,Chlorpheniramine,CYP2D6,Adverse effects,-
"",Dexchlorpheniramine,CYP2D6,Adverse effects,-
Antipsychotics,Aripiprazole,CYP2D6,Adverse effects,-
Brexpiprazole,CYP2D6,Adverse effects,-,
Clozapine,CYP1A2,Reduced / inadequate response,-,
Haloperidol,CYP2D6,Adverse effects,-,
Olanzapine,CYP1A2,Reduced / inadequate response,-,
Pimozide,CYP2D6,Adverse effects,,
Risperidone,CYP2D6,Adverse effects,DPWG3,
MEDICATIONS WITH MINOR PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
"",Zuclopenthixol,CYP2D6,Adverse effects,DPWG3
Antitussives,Dextromethorphan,CYP2D6,Altered response,-
Benzodiazepines,Clobazam,CYP2C19,Adverse effects,-
"",Diazepam,CYP2C19,Adverse effects,-
Beta blockers,Metoprolol,CYP2D6,Adverse effects,DPWG3
"",Propranolol,"CYP2D6CYP1A2",Altered response,-
Hypnotics,Melatonin,CYP1A2,Reduced / inadequate response,-
"Immunomodulatorsand antineoplastics",Tamoxifen,CYP2D6,Reduced / inadequate response,CPIC7
Miscellaneous,Cyclophosphamide,CYP2C19,Reduced / inadequate response,-
"",Eliglustat,CYP2D6,Adverse effects,TGA8
"",Naltrexone,OPRM1,"Associated with reducedresponse to naltrexone",
"",Proguanil,CYP2C19,Reduced / inadequate response,-
Neurological drugs,Tetrabenazine,CYP2D6,Adverse effects,FDA9
Opioid Analgesics,Morphine,OPRM1,"Associated with increasedtherapeutic and/or adverseeffects to morphine",-
"Proton pumpinhibitors",Dexlansoprazole,CYP2C19,"Increased therapeutic and/oradverse effects",FDA10
Esomeprazole,CYP2C19,"Increased therapeutic and/oradverse effects",-,
Lansoprazole,CYP2C19,"Increased therapeutic and/oradverse effects",-,
Omeprazole,CYP2C19,"Increased therapeutic and/oradverse effects",-,
Pantoprazole,CYP2C19,"Increased therapeutic and/oradverse effects",-,
Rabeprazole,CYP2C19,"Increased therapeutic and/oradverse effects",-,
MEDICATIONS WITH USUAL PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
"Angiotensin receptorblockers",Irbesartan,CYP2C9,"No altered effect predicted bygenotype",-
"",Losartan,CYP2C9,"No altered effect predicted bygenotype",-
"Anticholinergics(genitourinary)",Darifenacin,CYP2D6,"No altered effect predicted bygenotype",-
"",Fesoterodine,CYP2D6,"No altered effect predicted bygenotype",-
"",Tolterodine,CYP2D6,"No altered effect predicted bygenotype",-
Anticholinesterases,Donepezil,CYP2D6,"No altered effect predicted bygenotype",-
"",Galantamine,CYP2D6,"No altered effect predicted bygenotype",-
Anticoagulants,Acenocoumarol,"VKORC1CYP2C9",Normal acenocoumarol sensitivity,
Warfarin,"VKORC1CYP2C9",Normal warfarin sensitivity,FDA11,
MEDICATIONS WITH USUAL PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
"Antidepressants -other",Vortioxetine,CYP2D6,"No altered effect predicted bygenotype",-
"Antidepressants -SSRIs",Fluoxetine,"CYP2D6CYP2C9","No altered effect predicted bygenotype",-
"",Fluvoxamine,"CYP2D6CYP1A2","No altered effect predicted bygenotype",CPIC4
Antidiabetics,Glimepiride,CYP2C9,"No altered effect predicted bygenotype",-
"",Glyburide,CYP2C9,"No altered effect predicted bygenotype",-
Antiemetics,Metoclopramide,CYP2D6,"No altered effect predicted bygenotype",-
Antiepileptics,Phenytoin,CYP2C9,"No altered effect predicted bygenotype",CPIC12
Antihistamines,Promethazine,CYP2D6,Adverse effects,-
Antipsychotics,Chlorpromazine,CYP2D6,"No altered effect predicted bygenotype",-
"",Quetiapine,CYP3A4,"No altered effect predicted bygenotype",-
Beta blockers,Carvedilol,CYP2D6,"No altered effect predicted bygenotype",-
"",Nebivolol,CYP2D6,"No altered effect predicted bygenotype",-
Calcineurin inhibitors,Tacrolimus,CYP3A5,"No altered effect predicted bygenotype",CPIC13
"Glaucoma - ocularpreparations",Timolol,CYP2D6,"No altered effect predicted bygenotype",-
Miscellaneous,Atazanavir,CYP3A5,"No altered effect predicted bygenotype",-
NSAIDs,Celecoxib,CYP2C9,"No altered effect predicted bygenotype",-
"",Diclofenac,CYP2C9,"No altered effect predicted bygenotype",-
"",Flurbiprofen,CYP2C9,"No altered effect predicted bygenotype",-
"",Ibuprofen,CYP2C9,"No altered effect predicted bygenotype",-
"",Indomethacin,CYP2C9,"No altered effect predicted bygenotype",-
"",Mefenamic Acid,CYP2C9,"No altered effect predicted bygenotype",-
"",Meloxicam,CYP2C9,"No altered effect predicted bygenotype",-
"",Piroxicam,CYP2C9,"No altered effect predicted bygenotype",-
Opioid Analgesics,Codeine,"CYP2D6OPRM1","Associated with increasedsensitivity to codeine",CPIC14
"",Hydrocodone,CYP2D6,"No altered effect predicted bygenotype",
"",Oxycodone,CYP2D6,"No altered effect predicted bygenotype",DPWG3
"",Tramadol,CYP2D6,"No altered effect predicted bygenotype",DPWG3
Psychostimulants,Dextroamphetamine,CYP2D6,"No altered effect predicted bygenotype",-
MEDICATIONS WITH USUAL PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
"",Lisdexamfetamine,CYP2D6,"No altered effect predicted bygenotype",-
Statins,Atorvastatin,"SLCO1B1CYP3A4","No altered effect predicted bygenotype",-
Fluvastatin,"SLCO1B1CYP2C9","No altered effect predicted bygenotype",-,
Pravastatin,SLCO1B1,"No altered effect predicted bygenotype",-,
Rosuvastatin,SLCO1B1,"No altered effect predicted bygenotype",-,
Simvastatin,"SLCO1B1CYP3A4","No altered effect predicted bygenotype",CPIC15,
